Zobrazeno 1 - 10
of 3 424
pro vyhledávání: '"Benznidazole"'
Autor:
Maria Letizia Giancola, Andrea Angheben, Laura Scorzolini, Stefania Carrara, Ada Petrone, Antonella Vulcano, Raffaella Lionetti, Angela Corpolongo, Rosalia Marrone, Francesca Faraglia, Tommaso Ascoli Bartoli, Patrizia De Marco, Maria Virginia Tomassi, Carla Fontana, Emanuele Nicastri
Publikováno v:
Infectious Disease Reports, Vol 16, Iss 4, Pp 650-663 (2024)
Chagas disease (CD) is a parasitic infection endemic in Latin America and also affects patients in Western countries due to migration flows. This has a significant impact on health services worldwide due to its high morbidity and mortality burden. Th
Externí odkaz:
https://doaj.org/article/c7ccf87af0a44b22bd3190137d9cbf6a
Publikováno v:
Beilstein Journal of Nanotechnology, Vol 15, Iss 1, Pp 333-349 (2024)
Chagas disease (CD) is the most important endemic parasitosis in South America and represents a great socioeconomic burden for the chronically ill and their families. The only currently available treatment against CD is based on the oral administrati
Externí odkaz:
https://doaj.org/article/dcbc5b67189147859fc86859b71f208c
Autor:
Juliana Magalhães Chaves Barbosa, Yasmin Pedra-Rezende, Hílton Antônio Mata-Santos, Glaucia Vilar-Pereira, Tatiana Galvão de Melo, Isalira Peroba Ramos, Daniel Gibaldi, Otacilio C. Moreira, Daniela Ferreira Nunes, Marcos Meuser Batista, Joseli Lannes-Vieira, Anissa Daliry, Kelly Salomão
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 175, Iss , Pp 116742- (2024)
Chagasic chronic cardiomyopathy (CCC) is the primary clinical manifestation of Chagas disease (CD), caused by Trypanosoma cruzi. Current therapeutic options for CD are limited to benznidazole (Bz) and nifurtimox. Amiodarone (AMD) has emerged as most
Externí odkaz:
https://doaj.org/article/74fee9ebb1cf46189e361f19dbc83ea9
Autor:
Giuliana Muraca, María Esperanza Ruiz, Rocío C. Gambaro, Sebastián Scioli-Montoto, María Laura Sbaraglini, Gisel Padula, José Sebastián Cisneros, Cecilia Yamil Chain, Vera A. Álvarez, Cristián Huck-Iriart, Guillermo R. Castro, María Belén Piñero, Matias Ildebrando Marchetto, Catalina Alba Soto, Germán A. Islan, Alan Talevi
Publikováno v:
Beilstein Journal of Nanotechnology, Vol 14, Iss 1, Pp 804-818 (2023)
Chagas disease is a neglected endemic disease prevalent in Latin American countries, affecting around 8 million people. The first-line treatment, benznidazole (BNZ), is effective in the acute stage of the disease but has limited efficacy in the chron
Externí odkaz:
https://doaj.org/article/e99f913b717344ad8d5311428d1d8139
Autor:
Lucas Resende Dutra Sousa, Thays Helena Chaves Duarte, Viviane Flores Xavier, Aline Coelho das Mercês, Gabriel Maia Vieira, Maximiliano Delany Martins, Cláudia Martins Carneiro, Viviane Martins Rebello dos Santos, Orlando David Henrique dos Santos, Paula Melo de Abreu Vieira
Publikováno v:
Pharmaceutics, Vol 16, Iss 6, p 800 (2024)
Chagas disease (CD) is a worldwide public health problem. Benznidazole (BZ) is the drug used to treat it. However, in its commercial formulation, it has significant side effects and is less effective in the chronic phase of the infection. The develop
Externí odkaz:
https://doaj.org/article/34f81402df3141d89cb3dd2d51475105
Autor:
Simone Kann, Gustavo Concha, Hagen Frickmann, Ralf Matthias Hagen, Philipp Warnke, Ernst Molitor, Achim Hoerauf, Joy Backhaus
Publikováno v:
Journal of Clinical Medicine, Vol 13, Iss 9, p 2565 (2024)
Background: For indigenous people in Colombia, high infection rates with Chagas disease (CD) are known. Methods: In 2018 and 2020, nine villages were screened for CD. CD-positive patients could enter a drug observed treatment. While, in 2018, Benznid
Externí odkaz:
https://doaj.org/article/42386cfc1993460281571b49f48652a6
Autor:
Davi Alvarenga Lima, Leilane Oliveira Gonçalves, João Luís Reis-Cunha, Paul Anderson Souza Guimarães, Jeronimo Conceição Ruiz, Daniel Barbosa Liarte, Silvane Maria Fonseca Murta
Publikováno v:
Parasites & Vectors, Vol 16, Iss 1, Pp 1-18 (2023)
Abstract Background Chagas disease (CD), caused by the parasite Trypanosoma cruzi, is a serious public health concern in Latin America. Nifurtimox and benznidazole (BZ), the only two drugs currently approved for the treatment of CD, have very low eff
Externí odkaz:
https://doaj.org/article/0392c77ba8624f1ca7824862a93caf18
Autor:
Bianca Sabaini Pavan Tycha, Eros Antônio de Almeida, Rodrigo Gonçalves de Lima, Jamiro Silva da Wanderley, Luiz Cláudio Martins, Sandra Cecília Botelho Costa, Gláucia Elisete Barbosa Marcon
Publikováno v:
Asian Pacific Journal of Tropical Medicine, Vol 16, Iss 12, Pp 565-572 (2023)
Objective: To evaluate parasitemia by qPCR in patients undergoing etiological treatment and followed in a Brazilian reference center. Methods: Parasite load was quantified by qPCR in 32 participants with chronic Chagas disease who were treated with b
Externí odkaz:
https://doaj.org/article/f6b86afdfbe54416ad4c3dd268d43978
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.